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Abstract
Background Cell penetrating peptides have been successfully used to
mediate the intracellular delivery of a wide variety of molecules of
pharmacological interest. The main aim of the present work was to
evaluate the potential of the S413-PV cell penetrating peptide to mediate
the intracellular delivery of plasmid DNA, aiming at its use in gene therapy
applications. The S413-PV cell penetrating peptide is a chimeric peptide that
results from the combination of a cell penetrating sequence derived from the
Dermaseptin S4 peptide with the nuclear localization signal present in the
Simian Virus 40 (SV40) large T antigen.
Methods S413-PV cell penetrating peptide and cationic liposomes
composed of 1,2-dioleoyl-3-trimethylammonium-propane:1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine were complexed with pDNA at different
charge ratios. Complexation of pDNA was assessed by gel electrophore-
sis. Luciferase assay, fluorescence microscopy and fluorescence-activated cell
sorting analysis were used to evaluate reporter gene delivery to TSA and
HeLa cells. Cytotoxicity of the pDNA complexes was assessed by Alamar blue
assay.
Results Complexes obtained through electrostatic association of the S413-PV
cell penetrating peptide with plasmid DNA are able to very efficiently mediate
transfection, particularly at high peptide/DNA charge ratios. Additionally,
our results clearly demonstrate that, both in HeLa and TSA cells, ternary
complexes, resulting from association of cationic liposomes to peptide/DNA
complexes, are significantly more efficient in mediating transfection than the
corresponding peptide/DNA or cationic liposome/DNA complexes.
Conclusions Overall, our data highlight the potential of cell penetrating
peptides for the development of improved nonviral gene delivery systems.
Copyright  2008 John Wiley & Sons, Ltd.
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Introduction
Therapeutic benefit from gene therapy applications relies on the develop-
ment of delivery systems able to mediate high and sustained levels of gene
expression, at the same time as avoiding the safety concerns usually associ-
ated with the use of viral vectors. Despite extensive research on the rational
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improvement of nonviral gene delivery vectors, such as
cationic liposomes or polymers [1], these systems are
still far from being viable alternatives to the use of viral
vectors in gene therapy [2,3].
Cell penetrating peptides, a group of peptides able to
efficiently accumulate inside cells, have been successfully
used to mediate the intracellular delivery of a wide variety
of molecules of pharmacological interest, particularly
proteins, both in vitro and in vivo [4–14]. Although
the mechanisms underlying the cellular uptake of
these peptides and of their conjugates remain highly
debated, the efficient uptake of these peptides and, most
importantly, the ability shared by a considerable number
of cell penetrating peptides to accumulate inside the
nucleus of cells, render them particularly suited to act as
gene delivery vectors per se, or in association with other
existing nonviral systems. Even though the delivery of
peptides and proteins to the cytoplasm has been the major
focus of research on cell penetrating peptides, a number
of studies have focused on the use of cell penetrating
peptides to mediate the intracellular delivery of plasmid
DNA [15–26].
Cell penetrating peptides are usually short sequences
rich in basic amino acids, in some cases exhibiting the
ability to be arranged in amphipathic structures. The
peptides derived from the HIV-1 Tat protein and from the
homeodomain of the Antennapedia protein of Drosophila
(Tat and Penetratin peptides, respectively) [27,28], as
well as the synthetic Pep-1 peptide [29], are among
the best characterized cell penetrating peptides. The
S413-PV cell penetrating peptide is a chimeric peptide
that results from the combination of a cell penetrating
sequence derived from the Dermaseptin S4 peptide with
the well-characterized nuclear localization signal present
in the Simian Virus 40 (SV40) large T antigen [30].
Previously, we have demonstrated that the S413-PV
peptide is able to very efficiently accumulate inside live
cells, and particularly inside the nucleus, through a rapid,
dose-dependent and nontoxic process [31]. Moreover,
we provided evidence that, rather than endocytosis, the
cellular uptake of the S413-PV peptide is a consequence of
its direct translocation through cell membranes, following
conformational changes induced by peptide–membrane
interactions [32,33].
Nevertheless, it should be highlighted that the
internalization mechanism of cell penetrating peptides
is strongly influenced by the presence of a cargo, which
changes the size and charge of the resulting complex.
Endocytosis has been implicated as the mechanism
responsible for the internalization of different cell
penetrating peptides when associated with different types
of cargoes, regardless of the uptake mechanism of the cell
penetrating peptides alone [13].
The main aim of the present work was to evaluate the
potential of the S413-PV peptide to mediate the intracel-
lular delivery of plasmid DNA. The transfection efficiency
of S413-PV peptide/DNA complexes, as well as that of
ternary systems formed between the peptide/DNA com-
plexes and cationic liposomes, was evaluated, aiming
to explore a possible synergistic enhancement of gene
delivery mediated by the cationic liposomes. The results
obtained demonstrate that highly efficient transfection
can be achieved using complexes resulting from electro-
static association of the S413-PV cell penetrating peptide
with plasmid DNA. Experiments using peptides derived
from the S413-PV peptide demonstrated that the sequence
derived from the Dermaseptin S4 peptide, rather than the
nuclear localization signal (NLS), is crucial for efficient
transfection. Ternary complexes obtained by association
of cationic liposomes to peptide/DNA complexes, pre-
pared with the different peptides, mediated transfection
more efficiently than the corresponding peptide/DNA or
cationic liposome/DNA complexes. Notably, the trans-
fection efficiency of these ternary complexes was not
inhibited by the presence of serum, suggesting that these
systems may be suitable for in vivo administration.
Overall, our results strongly indicate that cell penetrat-
ing peptides, including the S413-PV peptide, can be of




HeLa cells (human epithelial cervical carcinoma) and
TSA cells (mouse mammary adenocarcinoma) were
maintained at 37 ◦C, under 5% CO2, in Dulbecco’s
Modified Eagle’s medium-high glucose (DMEM; Sigma,
St Louis, MO, USA) supplemented with 10% (v/v) heat-
inactivated fetal bovine serum (FBS; Biochrom KG, Berlin,
Germany.), and with 100 units of penicillin and 100 µg
of streptomycin (Sigma) per ml.
For flow cytometry experiments, 0.8 × 105 HeLa
cells/well or 1.1 × 105 TSA cells/well were seeded onto
12-well plates; for fluorescence microscopy studies,
0.8 × 105 HeLa cells/well or 0.9 × 105 TSA cells/well
were seeded onto 12-well plates containing 16 mm
glass coverslips; and for the luminescence experiments
(luciferase activity) 4.5 × 104 cells/well (HeLa or TSA)
were seeded onto 48-well plates. Cells were plated 24 h
prior to incubation with complexes.
Peptides
Peptide S413-PV (Table 1) was prepared as a C-terminal
amide by solid-phase methodologies based on clas-
sical Fmoc (1-(9H-fluoren-9-yl)-methoxycarbonyl)/tert-
Butyl chemistry [34]. Briefly, the peptide sequence was
assembled on a Fmoc-Rink-MBHA (p-{(R,S)-α-[1-(9H-
fluoren-9-yl)-methoxyformamido]-2,4-dimethoxybenzyl}-
phenoxyacetic acid-4-methylbenzhydrylamine) resin
(0.30 mmol/g), using DIC (diisopropylcarbodiim-
ide)/HOBt (1-hydroxybenzotriazole) in dichloromethane
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to promote coupling of the Fmoc-AA-OH (Nα-Fmoc-
protected amino acid), and 20 vol-% piperidine in N,N-
dimethylformamide for Fmoc-removal cycles. After acety-
lation of its N-terminal amino acid, the peptide was fully
deprotected and cleaved from resin by acidolytic treat-
ment with a TFA/TIS/H2O 95 : 2.5 : 2.5 (v/v/v) cocktail
for 3 h, after which the crude product was precipitated
with methyltertbutylether. The target peptide was iso-
lated in high purity (>95%) from the crude mixture
by preparative reverse phase-high performance liquid
chromatography and successfully identified by matrix-
assisted laser desorption ionization–time-of-flight mass
spectrometry) (not shown). NLS and scrambled peptides
(Figure 1A) of identical purity levels were obtained from
Thermo Electron GmbH, (Ulm, Germany), also as C-
terminal amides. In the reverse NLS peptide, the sequence
corresponding to the nuclear localization signal of the
SV40 large T antigen (amino acids 14–20) is inverted;
the scrambled peptide was generated on the basis of
S413-PV peptide sequence, so that the resulting peptide
had the same amino acid composition and overall charge,
but a distinct primary sequence. Both peptides were also
acetylated at their N-terminus. Freeze-dried peptides were
reconstituted in high purity water.
Concentration of S413-PV and related peptides was
determined by amino acid analysis and light absorption
at 280 nm. Amino acid analysis was performed in a
Beckman 6300 automatic analyser, (CA, USA), following
acid hydrolysis of the peptide.
Tat peptide 48–60 (CGRKKRRQRRRPP) was kindly
provided by Professor Bernard Lebleu (University of
Montpellier II, France).
Preparation of cationic liposomes
Small unilamellar vesicles (SUVs) were prepared
by extrusion of multilamellar vesicles composed of
the cationic lipid 1,2-dioleoyl-3-trimethylammonium-
propane (DOTAP; Avanti Polar Lipids, AL, USA) and
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE;
Avanti Polar Lipids), at a 1 : 1 molar ratio.
Lipid solutions in chloroform were mixed at the
desired molar ratio, and dried under vacuum, at room
temperature, using a rotary evaporator. The dried lipid
films were then hydrated with 1.0 ml high purity water,
and the multilamellar vesicles obtained were briefly
sonicated and extruded 21 times through two stacked
polycarbonate filters (pore diameter 50 nm) using a
Liposofast device (Avestin, Ontario, Canada.). The lipid
concentration of the resulting SUVs was determined by
the Bartlett method [35].
Preparation of complexes
Peptide/DNA complexes were prepared by mixing
1.0 µg of pEGFP-C1 plasmid DNA (Clontech, CA, USA.)
(fluorescence microscopy and flow cytometry) or 0.25 µg
Figure 1. Complexation of plasmid DNA by S413-PV, reverse NLS
and scrambled cell penetrating peptides. (A) Comparison of the
sequences of the S413-PV, reverse NLS and scrambled peptides
used in the present study. (B) Peptide/DNA complexes were
prepared by mixing plasmid DNA (pEGFP-C1) with increasing
amounts of S413-PV, reverse NLS or scrambled peptides, at
room temperature for 15 min. Formation of peptide/plasmid
DNA complexes was monitored by evaluating the electrophoretic
mobility of the different mixtures in a 1% agarose gel (0.5 µg
of plasmid DNA per lane). Free plasmid DNA is shown for
comparison
of pCMVluc encoding luciferase (a gift of Dr P. Felgner,
Vical, San Diego, CA, USA) (luciferase assay) in HEPES-
buffered saline solution (HBS; 140 mM NaCl, 10 mM
HEPES, pH 7.4) with different amounts of peptide
(depending on the desired charge ratio). The mixtures
were incubated for 15 min at room temperature to allow
formation of the complexes.
Complexes of peptide, DNA and cationic liposomes
(ternary complexes) were obtained by mixing pep-
tide/DNA complexes, prepared at different charge ratios,
with the cationic liposomes. Mixtures were then incubated
for 15 min, at room temperature.
Cationic liposome/DNA complexes were prepared by
mixing 1.0 µg of pEGFP-C1 plasmid DNA or 0.25 µg of
pCMVluc plasmid DNA with the cationic liposomes, in
order to achieve the desired charge ratio. The mixtures
were incubated for 15 min at room temperature to allow
formation of the complexes.
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Peptide/DNA, peptide/DNA/cationic liposome and
cationic liposome/DNA complexes were used immediately
after their preparation.
Complexes of plasmid DNA with Lipofectamine 2000
(Invitrogen, CA, USA.) were prepared accordingly to




Complexes were characterized with respect to their size
using a Coulter N4 Plus (Coulter Corporation, Miami,
FL, USA). The Coulter N4 Plus uses autocorrelation
spectroscopy of scattered laser light to determine the rate
of diffusion or Brownian motion of particles in suspension
and hence their size. The analysis was performed at
20 ◦C in HBS and the detection angle was fixed at 90◦.
Complexes were prepared immediately before analysis.
Complexation of plasmid DNA by the
S413-PV cell penetrating peptide and
derived peptides
Complexation of plasmid DNA by the S413-PV, reverse NLS
and scrambled peptides was evaluated by monitoring the
electrophoretic mobility of complexes of the peptides and
pEGFP-C1 plasmid, prepared at increasing peptide/DNA
charge ratios, as described above. The different complexes
were separated on a 1% agarose gel in Tris-acetate buffer
(0.5 µg of plasmid DNA per lane). The agarose gel was
stained with ethidium bromide.
Transfection studies
HeLa and TSA cells were incubated with either free
plasmid DNA or the different complexes (1.0 µg of pEGFP-
C1 or 0.25 µg of pLuc per well) at 37 ◦C for 4 h, in the
presence or absence of 10% (v/v) FBS. After this period,
the medium was replaced with fresh medium containing
10% (v/v) FBS, and the cells were further incubated for
48 h to allow gene expression. The transfection efficiency
mediated by the different complexes was evaluated by
analysing GFP expression by fluorescence microscopy
and/or flow cytometry, and by assessing luciferase
expression, by luminescence measurements.
For analysis of GFP expression by fluorescence
microscopy, 48 h post-transfection the cells were washed
with phosphate-buffered saline (PBS), fixed with 4%
paraformaldehyde for 15 min at room temperature, and
rinsed with PBS. The coverslips were then inverted
and mounted on glass slides with Vectashield mounting
medium (Vector Laboratories, Inc., Burlingame, CA,
USA). The cells were observed using a fluorescence
microscope, at ×200 magnification.
For flow cytometry analysis of GFP expression, 48 h
post-transfection, the cells were washed once with PBS
and detached with trypsin (10 min at 37 ◦C). The
cells were then further washed, resuspended in PBS,
and immediately analysed. Flow cytometry analysis was
performed, in live cells, using a Becton Dickinson, (NJ,
USA), FACSCalibur flow cytometer. Data were obtained
and analysed using CellQuest software. Live cells were
gated by forward/side scattering from a total of 10 000
events.
The quantification of luciferase expression in cell
lysates was evaluated by measuring light production
by luciferase in a luminometer (Lmax II384; Molecular
Devices, CA, USA.). Forty-eight hours post-transfection,
the cells were washed twice with PBS and lysis buffer
[1 mM dithiothreitol; 1 mM ethylenediaminetetraacetic
acid; 25 mM Tris-phosphate (pH 7.8); 8 mM MgCl2; 15%
glycerol; 1% (v/v) Triton X-100] was added to each well.
The protein content of the lysates was measured by the
DC Protein Assay reagent (Bio-Rad, Hercules, CA, USA)
using bovine serum albumin as the standard. The data
were expressed as RLU of luciferase per mg of total cell
protein.
Cell viability studies
Cell viability under the different experimental conditions
was assessed, in parallel experiments, by a modified Ala-
mar Blue assay [36]. Forty-seven hours post-transfection,
the cells were incubated with DMEM containing 10%
(v/v) Alamar Blue dye. After a 1-h incubation period at
37 ◦C, the absorbance of the medium was measured at
570 nm and 600 nm. Cell viability was calculated, as a
percentage of the nontransfected control cells, according:
Cell viability(% of control)
= [(A570 − A600)/(A′570 − A′600)] × 100
where A570 and A600 are the absorbances of the samples,
and A′570 and A′600 those of control cells, at the indicated
wavelengths.
Statistical analysis
All data are presented as mean ± SD. Data were analysed
using GraphPad Software, Inc., CA, USA. Statistical
significances of differences between data were evaluated
by t-test.
Results
Complexation of plasmid DNA by the
S413-PV cell penetrating peptide and
derived peptides
Given the polycationic nature of the S413-PV cell
penetrating peptide, its ability to bind and form complexes
with plasmid DNA was evaluated. Parallel experiments
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were performed with the reverse NLS and scrambled
peptides (Figure 1A), two peptides derived from the
S413-PV peptide, with similar physico-chemical properties
(peptide length, mass and charge).
Comparative analysis of the electrophoretic mobility
of complexes of plasmid DNA with the different
peptides, prepared at increasing peptide/DNA charge
ratios, showed that complexes prepared at charge ratios
higher than 3 : 2 do not migrate in an agarose gel
(Figure 1B), indicating a total neutralization of the DNA
negative charges by the peptides. At peptide/DNA charge
ratios below 3 : 2, a decrease in the intensity of the
bands corresponding to plasmid DNA was observed for
increasing amounts of peptide (Figure 1B), most likely
reflecting a partial complexation of the plasmid DNA
molecules by the different peptides.
Overall, these results demonstrate that the S413-PV,
reverse NLS or scrambled peptides are able to form
complexes through electrostatic interactions with plasmid
DNA, although an excess of peptide positive charge is
required for complete complexation of DNA.
Efficiency of S413-PV cell penetrating
peptide to mediate gene delivery
To evaluate the potential of the S413-PV cell penetrating
peptide to mediate the intracellular delivery of DNA, the
transfection efficiency of complexes of this peptide with
plasmid DNA encoding GFP, prepared at different charge
ratios, was determined in HeLa and TSA cells. Because
total complexation of plasmid DNA was achieved only at
peptide/DNA charge ratios higher than 3 : 2 (Figure 1B),
complexes prepared at 2 : 1 or higher charge ratios were
selected for these studies.
Fluorescence microscopy and flow cytometry analysis
of GFP expression revealed that the efficiency of the
different complexes to transfect HeLa cells is highly
dependent on their charge ratio. Complexes prepared
at a peptide/DNA charge ratio of 2 : 1 mediated low
efficiencies of transfection (approximately 10% of cells
transfected), whereas higher transfection efficiencies
(approximately 50% of cells transfected) were obtained
for those prepared at higher charge ratios (10 : 1)
(Figure 2A). Although lower levels of transfection were
observed in TSA cells for the same charge ratios (less than
20% of cells transfected at a peptide/DNA charge ratio
of 10 : 1), a similar dependence on the charge ratio was
observed (Figure 2B).
These results demonstrate that complexes formed upon
electrostatic interaction between the S413-PV peptide and
plasmid DNA, particularly at high peptide/DNA charge
ratios, are able to efficiently transfect both HeLa and TSA
cells.
Effect of peptide sequence on the
transfection efficiency mediated by
peptide/DNA complexes
To investigate the relevance of the Dermaseptin-
derived sequence and of the nuclear localization signal
to the efficiency of the overall process of gene
delivery, a comparative analysis of the transfection
efficiency mediated by the S413-PV peptide and by the
reverse NLS and scrambled peptides (Figure 1A) was
performed.
The results obtained from these experiments demon-
strated that, in both cell lines and at the different
peptide/DNA charge ratios tested, the reverse NLS
peptide mediated transfection at efficiencies compara-
ble to those observed with the S413-PV peptide. On
the other hand, transfection mediated by the scram-
bled peptide was consistently less efficient than that
obtained for the S413-PV and reverse NLS peptides
(Figure 3).
Interestingly, a general trend was observed for the
three peptides used in the experiments performed with
HeLa cells, showing increasing transfection efficiencies as
a result of the increase in the peptide/DNA charge ratio at
which the different complexes were prepared (Figures 3A
to 3C). In TSA cells, the same trend was observed for
the S413-PV and reverse NLS peptides, but not for the
scrambled peptide, for which very low efficiencies of
transfection were observed at any of the peptide/DNA
charge ratios tested (Figures 3B and 3C).
Overall, these results demonstrate that the Derma-
septin-derived sequence present in the S413-PV and
reverse NLS peptides (amino acids 1–13) plays an
important role in the ability of the peptide/DNA




Cationic liposomes have been extensively used to promote
the intracellular delivery of plasmid DNA, although the
efficiency of this process is rather low. To explore whether
association of cationic liposomes to peptide/plasmid
DNA complexes would result in an enhancement of
gene delivery, the transfection efficiency mediated by
complexes resulting from the interaction of these three
components (ternary complexes) was evaluated.
Comparative analysis of the transfection efficiency
mediated by ternary complexes and the corresponding
peptide/DNA complexes, performed by fluorescence
microscopy and flow cytometry, revealed that, in general,
addition of cationic liposomes to pre-formed peptide/DNA
complexes potentiates transfection. In HeLa cells the
enhancing effect of the addition of cationic liposomes
was relevant for peptide/DNA complexes prepared at
the lower charge ratios tested (2 : 1 and 5 : 1) (compare
Figures 3A and 4A). The transfection efficiency obtained
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Figure 2. Effect of charge ratio on the transfection efficiency mediated by S413-PV peptide/plasmid DNA complexes in HeLa and
TSA cells. (A) HeLa and (B) TSA cells were incubated with S413-PV peptide/plasmid DNA complexes prepared at different charge
ratios, for 4 h at 37 ◦C, as described in the Materials and Methods. Transfection efficiency mediated by the different complexes was
evaluated, 48 h post-transfection, by fluorescence microscopy and flow cytometry analysis of GFP expression
for the ternary complexes was independent of the
peptide used in their preparation and of peptide/DNA
charge ratio (Figure 4A). In TSA cells, the transfection
efficiency of the ternary complexes was slightly dependent
on the peptide/DNA charge ratio for the complexes
prepared with the S413-PV and the reverse NLS peptides
(Figure 4B). On the other hand, complexes prepared
with the scrambled peptide showed lower transfection
efficiency, which was independent of the peptide/DNA
charge ratio (Figure 4B).
It is important to emphasize that, under the same
experimental conditions and in both cell lines, the
efficiency of transfection mediated by the different ternary
complexes used in the present study was higher than that
achieved by standard cationic liposome/DNA complexes
prepared at an equivalent charge ratio, and comparable to
that obtained by the commercially available transfection
reagent Lipofectamine 2000 (Figures 4A and 4B). These
results clearly demonstrate that association of the S413-PV
cell penetrating peptide to plasmid DNA may constitute
a valuable approach to improve the efficiency of gene
delivery mediated by cationic liposomes.
Effect of peptide/DNA and ternary
complexes on cell viability
The toxicity of the peptide-based vectors used in the
present study was monitored by a modified Alamar Blue
assay, 48 h after transfection. As shown in Figure 5, no
significant toxicity was observed upon incubation of HeLa
or TSA cells with complexes prepared at the 2 : 1 and
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Figure 3. Effect of peptide sequence on the efficiency of transfection mediated by peptide/plasmid DNA complexes in HeLa and
TSA cells. (A) HeLa and (B) TSA cells were incubated with free plasmid DNA and complexes of S413-PV, reverse NLS or scrambled
peptides with plasmid DNA, prepared at different charge ratios, for 4 h at 37 ◦C, as described in the Materials and Methods.
Forty-eight hours post-transfection, the efficiency of transfection was evaluated by flow cytometry. (C) Representative images from
fluorescence microscopy analysis of cells transfected with complexes of S413-PV, reverse NLS or scrambled peptides with plasmid
DNA, prepared at the 10 : 1 peptide/DNA charge ratio. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared to free DNA, and ##p < 0.01
compared to 10 : 1 scrambled/DNA
5 : 1 peptide/DNA charge ratios, independently of the
peptide used. Complexes resulting from the interaction of
the S413-PV or reverse NLS peptides with DNA prepared
at the highest charge ratio (10 : 1), which mediated the
highest efficiencies of transfection, induced a significant
decrease in cell viability (Figures 5A and 5B), presumably
caused by interaction of the large excess of free peptide
with cell membranes.
Incubation of HeLa cells with ternary complexes
induced levels of toxicity slightly higher than those
observed for the corresponding peptide/DNA complexes
(Figure 5C). Of note, a reduction in cell viability
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induced by the ternary complexes prepared at the
10 : 1:1 charge ratio was similar to that obtained by
the Lipofectamine 2000 complexes (Figure 5C). Parallel
experiments performed with TSA cells showed that
the levels of toxicity induced by ternary complexes
were similar to those observed for the corresponding
peptide/DNA complexes (Figure 5D). Decrease in cell
viability was only significant for complexes prepared
with the reverse NLS peptide at the highest charge ratio
(Figure 5D).
Figure 4. Efficiency of transfectionmediated by peptide/plasmid
DNA/cationic liposome complexes (ternary complexes) in HeLa
and TSA cells. (A) HeLa and (B) TSA cells were incubated
with free plasmid DNA, cationic liposome/DNA complexes,
Lipofectamine 2000-based complexes and the different ternary
complexes for 4 h at 37 ◦C, as described in the Materials and
Methods. Transfection efficiency was evaluated, 48 h later, by
flow cytometry analysis of GFP expression. Ternary complexes
were obtained by the addition of cationic liposomes composed
of DOTAP :DOPE (1 : 1 molar ratio) to complexes of S413-PV,
reverse NLS or scrambled peptides with plasmid DNA, prepared
at different peptide/DNA charge ratios. ∗p < 0.05, ∗∗p < 0.01
compared to cationic liposome/DNA 1 : 1 complexes




The inhibition of gene delivery by serum is known as
one of the major limitations associated with the in vivo
application of nonviral vectors. To evaluate the effect of
serum on the stability of the systems described in the
present study, transfection experiments were performed
in both HeLa and TSA cells, in the presence or absence of
10% serum, and the transfection activity of the different
complexes was assessed by measuring luciferase activity
(Figures 6A and 6B).
The results obtained from these experiments demon-
strated that the transfection efficiency of the different
delivery systems is not inhibited by the presence of serum
(Figures 6A and 6B). In some cases, the transfection effi-
ciency of the complexes in the presence of serum was
even potentiated (Figures 6A and 6B). Importantly, in the
presence of serum the toxicity induced by ternary com-
plexes was maintained or even reduced, depending on
the cell line and charge ratio tested (Figures 6C and 6D).
Overall, these results demonstrate the suitability of the
carrier systems developed in the present study for the
delivery of therapeutically relevant plasmid DNA in vivo.
Comparative analysis of the
transfection activity mediated by
ternary complexes prepared with the
S413-PV and Tat peptides
To assess the potential of the S413-PV peptide with
respect to other more extensively studied cell penetrating
peptides, the biological activity of the most effective
S413-PV-based formulations was compared with that of
equivalent formulations prepared with the Tat peptide.
These studies were performed in TSA cells due to the
lower toxicity observed in this cell line (Figure 5).
The results obtained from these experiments showed
that ternary complexes prepared with the S413-PV or
Tat peptides mediate transfection at comparable levels,
although at the lowest charge ratio the former displayed
a slightly better performance (Figure 7A). Interestingly,
the transfection activity of ternary complexes containing
the Tat peptide increased with increasing charge
ratios, similarly to what was observed for S413-PV
peptide/DNA/cationic liposome complexes (Figure 7A).
As shown in Figure 7B, no significant toxicity was
observed upon incubation of TSA cells with the ternary
complexes, independently of the peptide used.
Physicochemical characterization of
complexes
Because the efficacy to deliver genetic material inside
target cells is strongly dependent on the physicochemical
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Figure 5. Effect of peptide/DNA and peptide/plasmid DNA/cationic liposome complexes on cell viability. (A, C) HeLa and (B, D)
TSA cells were incubated with free plasmid DNA, cationic liposome/DNA complexes, Lipofectamine 2000-based complexes and the
different (A, B) peptide/plasmid DNA complexes, or (C, D) peptide/plasmid DNA/cationic liposome complexes, for 4 h at 37 ◦C, as
described in the Materials and Methods. Forty-eight hours post-transfection, cell viability was evaluated by the Alamar Blue assay.
Cell viability is expressed as the percentage of control (nontransfected cells). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared to free
DNA
properties of the carrier systems, the different complexes
used in the present study were characterized with respect
to their size.
As shown in Table 1, lipoplexes prepared from
DOTAP : DOPE (1 : 1) cationic liposomes at the 1/1
lipid/DNA (+/−) charge ratio exhibited the smallest
mean diameter (approximately 640 nm). On the other
hand, complexes prepared with the S413-PV, reverse NLS
and scrambled peptides at different charge ratios (2 : 1,
5 : 1 and 10 : 1) exhibited the largest mean diameters
(1900–2900 nm).
Addition of DOTAP : DOPE (1 : 1) cationic liposomes
to any of the peptide/DNA complexes resulted in a
significant decrease of the size of the resulting complexes
(approximately 600–1200 nm).
Discussion
Accumulating evidences have demonstrated the capacity
of cell penetrating peptides to mediate intracellular
delivery of a wide variety of exogenous molecules,
especially peptides, proteins and small nucleic acid
molecules (oligonucleotides, siRNA). A number of studies
have also addressed the potential of cell penetrating
peptides for the delivery of plasmid DNA, either alone
or in association with existing nonviral gene delivery
vectors, such as cationic liposomes and cationic polymers
[15–26].
In the present study, we evaluated the potential use of
the S413-PV cell penetrating peptide for the intracellular
delivery of plasmid DNA.
Copyright  2008 John Wiley & Sons, Ltd. J Gene Med 2008; 10: 1210–1222.
DOI: 10.1002/jgm
S413-PV peptide for plasmid DNA delivery 1219
Figure 6. Effect of serum on the efficiency of transfection of ternary complexes based on the S413-PV peptide in HeLa and TSA cells.
(A, C) HeLa and (B, D) TSA cells were incubated with ternary complexes for 4 h at 37 ◦C, in the presence or absence of 10% serum,
as described in the Materials and Methods. Ternary complexes were obtained by the addition of cationic liposomes composed of
DOTAP :DOPE (1 : 1 molar ratio) to complexes of S413-PV peptide with plasmid DNA, prepared at different peptide/DNA charge
ratios. (A, B) Transfection efficiency was evaluated, 48 h later, by measuring luciferase activity. (C, D) In parallel experiments, cell
viability was evaluated by the Alamar Blue assay. Cell viability is expressed as the percentage of control (nontransfected cells).
∗p < 0.05, compared to cells treated with the same formulation but in the absence of serum
Assessment of the biological activity of complexes
resulting from the electrostatic interaction between
the S413-PV cell penetrating peptide and plasmid
DNA clearly demonstrated that these complexes are
able, per se, to efficiently mediate transfection in
two cell lines (HeLa and TSA cells). The additional
observation that transfection efficiency was significantly
improved with an increase of the charge ratio at
which peptide/DNA complexes were prepared suggests
that an excess of positively charged peptide promotes
transfection, most likely due to transient membrane
destabilization induced by the peptide. Interestingly,
Deshayes et al. have demonstrated that the intracellular
delivery of DNA oligonucleotides by the MPG peptide,
a chimeric peptide that results from the combination
of a hydrophobic domain and the SV40 large T antigen
nuclear localization signal, involves the formation of pore-
like structures consisting of peptide molecules inserted
into the lipid bilayer [37]. Although we have previously
demonstrated that the cellular uptake of the S413-PV
cell penetrating peptide occurs mainly through a non-
endocytic mechanism involving direct translocation of
the peptide across membranes [31–33], it is likely
that alternative mechanisms, the most prominent being
endocytosis, are involved in the cellular uptake of
peptide/DNA complexes.
In both HeLa and TSA cell lines, complexes prepared
with the S413-PV or reverse NLS peptides mediated
transfection at significantly higher efficiencies than those
containing the scrambled peptide, demonstrating the
importance of the cell penetrating sequence derived
from the Dermaseptin S4 peptide (amino acids 1–13)
to the transfection process. In this context, it should be
noted that the S413-PV and reverse NLS peptides, which
contain the Dermaseptin-derived sequence, undergo
significant conformational changes in the presence of
target membranes, which are intricately related to the
ability of these peptides to translocate across membranes
[32,33].
Moreover, these results strongly suggest that the NLS
present in the C-terminus of the S413-PV peptide (amino
acids 14–20) is not critical to the process of intracellular
gene delivery. However, because these experiments were
performed in dividing cells, the active nuclear import
of the plasmid DNA mediated by the NLS may have
been overridden by the nuclear membrane disassembly
events that occur during mitosis, which facilitate the
nuclear transport of the delivered molecules [38–40].
Independently of its role in promoting the nuclear import
of plasmid molecules, the NLS confers a high positive
charge density to the S413-PV peptide and its derivatives,
a feature that is, most likely, crucial to the efficient
complexation of DNA molecules by these peptides.
Different efficiencies of transfection were observed
in the two cell lines. Approximately 50% of HeLa
cells were transfected, while no more than 15% of
transfection was observed in TSA cells. Differences in the
composition of the extracellular matrix, which is known to
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Figure 7. Transfection activity of ternary complexes based on
S413-PV and Tat peptides. TSA cells were incubated with the
different ternary complexes for 4 h at 37 ◦C, as described in the
Materials and Methods. Ternary complexes were obtained by
the addition of cationic liposomes composed of DOTAP :DOPE
(1 : 1 molar ratio) to complexes of S413-PV, or Tat peptides
with plasmid DNA, prepared at different peptide/DNA charge
ratios. (A) Transfection activity was evaluated, 48 h later, by
measuring luciferase activity. (B) In parallel experiments, cell
viability was evaluated by the Alamar Blue assay. Cell viability
is expressed as the percentage of control (nontransfected cells).
∗p < 0.05, compared to cells treated with Tat/DNA/cationic
liposome complexes of the same charge ratio
contain molecules that interact with the delivery systems
facilitating their uptake, in the efficiency of intracellular
trafficking or in the mitotic rate of these cells may explain
the observed differences in transfection efficiencies.
To further evaluate the potential of the S413-PV cell
penetrating peptide for gene delivery applications, we
assessed the transfection efficiency of complexes con-
taining cationic liposomes, which have been extensively
used for nonviral gene delivery [2,41], and the differ-
ent peptides. Overall, ternary complexes obtained by the
addition of cationic liposomes to peptide/DNA complexes






DOTAP : DOPE/DNA 1 : 1 638 ± 346.3
S413-PV/DNA 2 : 1 2718 ± 131.7
5 : 1 2237 ± 660.93
10 : 1 2648 ± 414.7
S413-PV/DNA/DOTAP : DOPE 2 : 1:1 784 ± 555.34
5 : 1:1 680 ± 619.61
10 : 1:1 863 ± 378.27
Reverse NLS/DNA 2 : 1 2358 ± 388.82
5 : 1 2424 ± 407.04
10 : 1 2881 ± 112.85
Reverse NLS/DNA/DOTAP : DOPE 2 : 1:1 599 ± 337.84
5 : 1:1 968 ± 340.32
10 : 1:1 1066 ± 117.16
Scrambled/DNA 2 : 1 1927 ± 617.43
5 : 1 2599 ± 409.22
10 : 1 2839 ± 92.82
Scrambled/DNA/DOTAP : DOPE 2 : 1:1 976 ± 87.62
5 : 1:1 1180 ± 216.35
10 : 1:1 845 ± 267.9
aDOTAP : DOPE (1 : 1) liposomes were prepared as described in the
Materials and Methods.
bPeptide/DNA (+/−) or peptide/DNA/cationic liposome (+/−/+) charge
ratios, where applicable; cresults represent the mean ± SD from three
independent experiments.
were significantly more efficient than the correspond-
ing peptide/DNA complexes, suggesting a synergistic
effect between the cationic liposomes and the peptides
to enhance gene delivery. In HeLa cells, however, the
peptide/DNA complexes prepared at the highest charge
ratio exhibited the highest transfection activity, show-
ing no improvement upon the addition of the cationic
liposomes. Importantly, in both cell lines, transfection
efficiencies obtained with ternary complexes containing
the S413-PV peptide were comparable with those obtained
with Lipofectamine 2000.
Similar transfection efficiencies were observed in HeLa
cells, for the ternary complexes independently of the
charge ratio and the peptide used in their preparation.
A possible explanation is that the addition of cationic
liposomes to peptide/DNA complexes induces changes in
the overall structure of the complexes making endocytosis
the main route of uptake and masking the cell penetrating
properties of the peptides. In TSA cells, the same
dependence on the charge ratio was observed for
the peptide/DNA and ternary complexes prepared with
S413-PV and reverse NLS peptides, the more positively
charged complexes being the most efficient to deliver
plasmid DNA. It is possible that the main mechanisms
responsible for internalization of the complexes in these
cells are different from those in HeLa cells. Given the
high endocytic capacity of HeLa cells, it is reasonable
to assume that in these cells the ternary complexes are
mainly internalized by endocytosis, whereas, in TSA cells,
in which endocytosis may not have such an important
role, the presence of the peptide plays a determinant role
in the uptake of the complexes.
Remarkably, the efficiency of transfection achieved
by most ternary complexes used in the present study
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was significantly higher than that obtained by cationic
liposome/DNA complexes. These results suggest that
condensation of DNA by cell penetrating peptides,
in particular the S413-PV and derivative peptides,
prior to the addition of cationic liposomes, constitutes
a very promising approach to enhance transfection
mediated by cationic liposomes. The lower transfection
efficiencies observed when ternary complexes were
prepared by addition of the different peptides to cationic
liposome/DNA complexes reinforce this possibility (M.
Mano, A. Henriques, A. Paiva, S. Simo˜es and M.C.
Pedroso de Lima, unpublished work). Changes in the
physicochemical properties of peptide/DNA complexes
upon addition of cationic liposomes, which may confer
extra protection and/or facilitate the intracellular traffic
of the carried DNA molecules, may also account for the
observed differences in transfection efficiency. In this
regard, it is important to refer that size determination
revealed important differences among the different
complexes described in the present study. The smaller size
exhibited by the ternary complexes is probably critical for
their improved efficacy in comparison to the peptide/DNA
systems, of larger sizes. Most likely there is a threshold
size above which internalization of complexes by the
target cells becomes less efficient.
Complexes containing the S413-PV and reverse NLS
peptides prepared at the highest charge ratio tested
induced significant levels of cytotoxicity, presumably
reflecting membrane destabilization. Nonetheless, the
high transfection efficiencies (approximately 50% of cells
transfected, for HeLa cells) achieved by ternary complexes
with charge ratios at which they have no significant effect
on cell viability (2 : 1:1 and 5 : 1:1 charge ratios), are
noteworthy, especially when put in perspective with other
existing nonviral gene delivery vectors.
The transfection efficiency of the ternary complexes
described in the present study was not inhibited (in some
cases was even potentiated) by the presence of 10%
serum, and their cytotoxicity was, in general, decreased,
demonstrating the suitability of these systems for in vivo
applications. The possibility of an immunological response
against these complexes should, however, be taken into
account when considering in vivo experiments. Although
no studies on this issue have been addressed subject
for the S413-PV peptide, it has been shown that other
cell penetrating peptides containing positively charged
amino acids do not induce inflammatory cytokines or
anti-peptide antibodies when administered in vivo [42].
Although conflicting results have been reported
regarding the transfection ability of complexes prepared
by electrostatic association of the Tat peptide with
plasmid DNA [16–18,43], it is interesting to note that
the addition of cationic liposomes or cationic polymers
to peptide/DNA complexes was shown to improve
transfection [16,18,20,25]. In the present study, no
significant transfection was observed for Tat peptide/DNA
complexes (data not shown). However, as reported here
for the S413-PV-based systems, the addition of cationic
liposomes to Tat peptide/DNA complexes enhanced the
efficacy of these systems. Comparison of the ternary
complexes based on the S413-PV and Tat peptides
demonstrated that the complexes based on the S413-PV
cell penetrating peptide described in the present study
have a potential equivalent or superior to the systems
based on the Tat peptide to mediate intracellular gene
delivery.
Overall, the results gathered in the present manuscript
demonstrate the capacity of the S413-PV cell penetrating
peptide, either per se or in association with cationic
liposomes, to very efficiently mediate the intracellular
delivery of a transgene, highlighting the potential use of
cell penetrating peptides for the development of improved
nonviral gene delivery vectors.
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